Opus Health
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to treat inherited retinal diseases (IRDs), with a focus on restoring vision and preventing blindness.
Profile
Develops gene therapies to treat inherited retinal diseases and prevent blindness.
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to treat inherited retinal diseases (IRDs), with a focus on restoring vision and preventing blindness. Founded in Research Triangle Park, North Carolina, the company went public under the ticker IRD. Its lead programs target genetic mutations causing retinal degeneration, including LCA5, BEST1, RDH12, MERTK, and RHO.
As of Q1 2026, Opus Genetics reported a cash runway extending into 2029, positioning it to advance multiple clinical programs toward pivotal trials and potential FDA approvals. The company's most advanced candidate, OPGx-LCA5, showed promising six-month pediatric data with improvements in cone-mediated function and visual acuity, and was accepted into the FDA's Rare Disease Evidence Principles (RDEP) program. OPGx-BEST1 completed Cohort 1 enrollment in its Phase 1/2 trial, with topline data expected in September 2026.
Earlier-stage programs, including OPGx-RDH12 and OPGx-MERTK, are funded by external alliances and expected to enter clinical testing in late 2026. Opus Genetics operates with a precision-targeted approach, leveraging AAV vectors to deliver functional genes to photoreceptors. Its upcoming R&D Science Forum in June 2026 will highlight pipeline progress and market opportunities in IRDs.
Who buys this
- Patients with inherited retinal diseases (IRDs)
- Specialty ophthalmology clinics and hospitals
- Biopharmaceutical partners for co-development
- Government and rare disease research consortia
Strengths and what to watch
Strengths
- Strong clinical pipeline with multiple gene therapy candidates nearing pivotal trials.
- Financial stability with cash runway into 2029, supporting long-term R&D.
- Strategic alliances (e.g., RDH12 Alliance, Abu Dhabi’s Healthcare Research and Innovation Fund) providing non-dilutive funding.
Watch for
- Regulatory risks: FDA acceptance of single-study evidence under RDEP remains untested for LCA5.
- Clinical trial delays: Enrollment and manufacturing timelines for pivotal Phase 3 trials could slip.
- Competitive pressure: Other gene therapy developers targeting overlapping IRD indications.
Recent moves
Key Information
- Founded
- 2025
- Headquarters
- Research Triangle Park, North Carolina
Frequently Asked Questions
What does Opus Genetics specialize in?
Opus Genetics develops gene therapies to treat inherited retinal diseases (IRDs), focusing on restoring vision and preventing blindness. Their clinical-stage programs target genetic mutations like LCA5 and BEST1, using AAV vectors to deliver functional genes to photoreceptors. The company is based in Research Triangle Park, North Carolina.
What are Opus Genetics' most advanced gene therapy candidates?
Opus Genetics' lead candidates include OPGx-LCA5, which showed improved visual acuity in pediatric trials, and OPGx-BEST1, currently in Phase 1/2 trials. Earlier-stage programs target RDH12 and MERTK mutations, with clinical testing expected in late 2026. The company focuses on pivotal trials for FDA approval.
How is Opus Genetics funded for its clinical trials?
Opus Genetics has a cash runway extending into 2029, supporting its clinical programs. External alliances, like the RDH12 Alliance and Abu Dhabi’s Healthcare Research and Innovation Fund, provide non-dilutive funding. This financial stability helps advance multiple gene therapy candidates toward FDA approval.
What inherited retinal diseases does Opus Genetics target?
Opus Genetics targets IRDs caused by mutations in genes like LCA5, BEST1, RDH12, MERTK, and RHO. These mutations lead to retinal degeneration and vision loss. The company’s therapies aim to restore function in photoreceptors, offering potential treatments for patients with these rare genetic conditions.
When will Opus Genetics release clinical trial results for OPGx-BEST1?
Opus Genetics expects topline data from its OPGx-BEST1 Phase 1/2 trial in September 2026. Cohort 1 enrollment is complete, and the trial evaluates the therapy’s safety and efficacy for BEST1-related retinal diseases. Results will inform further development and potential FDA submissions.
What are the risks facing Opus Genetics' gene therapies?
Opus Genetics faces regulatory risks, as FDA acceptance of single-study evidence under RDEP is untested. Clinical trial delays in enrollment or manufacturing could impact timelines. Competition from other gene therapy developers targeting similar IRD indications also poses challenges for market differentiation and approval.
Sources
- www.sec.gov — Q1 2026 financial results and clinical pipeline updates.